Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665256 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
A Phase 2 study of Idiopathic Inflammatory Myopathies, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT06665256 is a Phase 2 study of Idiopathic Inflammatory Myopathies that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 123 participants, below the 191-participant average among 7 other Idiopathic Inflammatory Myopathies trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06665256, a Phase 2 study of Idiopathic Inflammatory Myopathies, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
Conditions Studied
Interventions
- BIOLOGICAL Rapcabtagene autoleucel
- OTHER Active Comparator Option
Study Locations (20)
Other
- Novartis Investigative Site - Brest
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Rennes
- Novartis Investigative Site - Aachen
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Mainz
- Novartis Investigative Site - Nuremberg
- Novartis Investigative Site - Ulm
- Novartis Investigative Site - Haifa
Illinois
- Northwestern University - Chicago
- Northwestern University - Chicago
Alabama
- University Of Alabama - Birmingham
Florida
- FL Medical Clinic Orlando Health - Zephyrhills
Iowa
- University Of Iowa - Iowa City
Utah
- LDS Hospital - Salt Lake City
North Rhine-Westphalia
- Novartis Investigative Site - Cologne
Saxony
- Novartis Investigative Site - Leipzig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2030-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06665256
The ClinicalTrials.gov registry entry for NCT06665256 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 7 other Idiopathic Inflammatory Myopathies trials with a reported enrollment target (36% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Inflammatory Myopathies appearing as the primary indexed condition, and to 2 interventions - of which Rapcabtagene autoleucel is the first listed.
NCT06665256 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT06665256 about?
NCT06665256 is a clinical study titled "Phase 2 Study of Rapcabtagene Autoleucel in Myositis". A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
What is the current status of trial NCT06665256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2024-12-17. Estimated completion is 2030-07-17.
What conditions does trial NCT06665256 study?
This clinical trial studies the following conditions: Idiopathic Inflammatory Myopathies.
What interventions are being tested in trial NCT06665256?
The interventions under investigation include: Rapcabtagene autoleucel (BIOLOGICAL), Active Comparator Option (OTHER).
Who is sponsoring clinical trial NCT06665256?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665256 being conducted?
This trial has 20 study locations across Alabama, Florida, Illinois, Iowa, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Inflammatory Myopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
RECRUITING · Early Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
-
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.